Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene‑1‑carboxamide is a synthetic small molecule compound with the molecular formula C25H22N2O4. It is listed in pharmaceutical compound libraries and referenced as VEGFR-IN-V in some chemical databases. The structure features a naphthalene carboxamide core substituted with a cyclopropyl group and an ether-linked dimethoxyquinoline moiety. While it appears in drug screening collections (such as ZINC15), there is no evidence of clinical development or approval for any therapeutic indication. Its mechanism of action has not been explicitly described in the available literature; however, based on its code name (VEGFR-IN-V), it may have been designed or investigated as an inhibitor of vascular endothelial growth factor receptor (VEGFR), which are targets commonly explored for antiangiogenic cancer therapies[2][1][7]. No information about clinical trials or marketed products was found.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-cyclopropyl-6-[(6,7-dimethoxyquinolin-4-yl)oxy]naphthalene-1-carboxamide.